CAR-T Cells and the Kidney: Insights from the WHO Safety Database.
Journal
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
ISSN: 1179-190X
Titre abrégé: BioDrugs
Pays: New Zealand
ID NLM: 9705305
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
accepted:
06
04
2023
medline:
26
6
2023
pubmed:
11
5
2023
entrez:
11
5
2023
Statut:
ppublish
Résumé
Chimeric antigen receptor T (CAR-T) cells have proven to be a game changer for treating several hematologic malignancies. Randomized controlled trials have highlighted potential life-threatening adverse drug reactions (ADRs), including cytokine release syndrome (CRS). Acute renal failure (ARF) has also been reported in 20% of the patients treated. However, an analysis of renal safety supported by large-scale real-life data seems warranted. We queried VigiBase® for all reports of the Standardised MedDRA Query "acute renal failure" (ARF) involving a CAR-T cell, registered until 24 July 2022. Disproportionality for this ADR was analyzed through calculation of the Information Component [IC (95% confidence interval)]. A positive lower end of the 95% confidence interval of the IC is the threshold used in statistical signal detection in VigiBase®. The same analysis was carried out for various hydroelectrolytic disorders. We gathered 224 reports of ARF, and 125 reports of hydroelectrolytic disorders involving CAR-T cells. CAR-T cells were disproportionately reported with ARF [IC 1.5 (1.3-1.7)], even after excluding reports mentioning CRS. A significant disproportionate reporting was also found for hypernatremia [IC 3.1 (2.2-3.8)], hyperphosphatemia [IC 3.1 (1.8-3.9)], hypophosphatemia [IC 2.0 (0.6-2.9)], metabolic acidosis [IC 1.8 (1.2-2.2)], hyponatremia [IC 1.6 (1.1-2.0)], and hypercalcemia [IC 1.4 (0.5-2.1)]. There was no disproportionate reporting of dyskalemia. This study is limited by the inherent flaws of pharmacovigilance approaches. Nonetheless, our findings suggest that ARF and an array of hydroelectrolytic disorders are potential ADRs of CAR-T cell therapy, in real-life settings and in a nonselected population.
Sections du résumé
BACKGROUND
BACKGROUND
Chimeric antigen receptor T (CAR-T) cells have proven to be a game changer for treating several hematologic malignancies. Randomized controlled trials have highlighted potential life-threatening adverse drug reactions (ADRs), including cytokine release syndrome (CRS). Acute renal failure (ARF) has also been reported in 20% of the patients treated. However, an analysis of renal safety supported by large-scale real-life data seems warranted.
PATIENTS AND METHODS
METHODS
We queried VigiBase® for all reports of the Standardised MedDRA Query "acute renal failure" (ARF) involving a CAR-T cell, registered until 24 July 2022. Disproportionality for this ADR was analyzed through calculation of the Information Component [IC (95% confidence interval)]. A positive lower end of the 95% confidence interval of the IC is the threshold used in statistical signal detection in VigiBase®. The same analysis was carried out for various hydroelectrolytic disorders.
RESULTS
RESULTS
We gathered 224 reports of ARF, and 125 reports of hydroelectrolytic disorders involving CAR-T cells. CAR-T cells were disproportionately reported with ARF [IC 1.5 (1.3-1.7)], even after excluding reports mentioning CRS. A significant disproportionate reporting was also found for hypernatremia [IC 3.1 (2.2-3.8)], hyperphosphatemia [IC 3.1 (1.8-3.9)], hypophosphatemia [IC 2.0 (0.6-2.9)], metabolic acidosis [IC 1.8 (1.2-2.2)], hyponatremia [IC 1.6 (1.1-2.0)], and hypercalcemia [IC 1.4 (0.5-2.1)]. There was no disproportionate reporting of dyskalemia.
CONCLUSIONS
CONCLUSIONS
This study is limited by the inherent flaws of pharmacovigilance approaches. Nonetheless, our findings suggest that ARF and an array of hydroelectrolytic disorders are potential ADRs of CAR-T cell therapy, in real-life settings and in a nonselected population.
Identifiants
pubmed: 37166707
doi: 10.1007/s40259-023-00599-1
pii: 10.1007/s40259-023-00599-1
pmc: PMC10287817
doi:
Substances chimiques
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
521-530Informations de copyright
© 2023. The Author(s).
Références
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Curr Opin Crit Care. 2022 Oct 1;28(5):540-550
pubmed: 35950720
Kidney Int. 2018 Aug;94(2):315-325
pubmed: 29861060
Kidney Int Rep. 2021 Feb 17;6(5):1416-1422
pubmed: 34013119
Cancer Immunol Res. 2022 Dec 2;10(12):1433-1440
pubmed: 36259217
Am J Hematol. 2021 Sep 1;96(9):1101-1111
pubmed: 34057232
Eur J Clin Pharmacol. 1998 Jun;54(4):315-21
pubmed: 9696956
Biol Blood Marrow Transplant. 2020 Jun;26(6):1071-1076
pubmed: 32088364
Life (Basel). 2020 Aug 05;10(8):
pubmed: 32764444
Blood. 2010 Nov 18;116(20):4099-102
pubmed: 20668228
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
N Engl J Med. 2011 Aug 25;365(8):725-33
pubmed: 21830940
Cancer Discov. 2017 Oct;7(10):OF1
pubmed: 28887358
Clin J Am Soc Nephrol. 2018 May 7;13(5):796-798
pubmed: 29523675
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
Am J Kidney Dis. 2008 Jul;52(1):144-53
pubmed: 18468754
Blood. 2017 Dec 14;130(24):2594-2602
pubmed: 28928126
Drug Saf. 2022 Aug;45(8):891-908
pubmed: 35829913
Nat Rev Clin Oncol. 2021 Nov;18(11):715-727
pubmed: 34230645
Stem Cell Res Ther. 2021 Jan 25;12(1):81
pubmed: 33494834
Am J Kidney Dis. 2020 Jul;76(1):63-71
pubmed: 31973908
Clin J Am Soc Nephrol. 2022 Sep;17(9):1385-1398
pubmed: 35338071
Blood. 2023 Feb 9;141(6):673-677
pubmed: 36332168
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
Autoimmun Rev. 2022 Jan;21(1):102931
pubmed: 34481941
Cells. 2022 Dec 10;11(24):
pubmed: 36552755
Clin J Am Soc Nephrol. 2022 Jun;17(6):922-933
pubmed: 35063968
Blood Adv. 2020 Feb 25;4(4):676-686
pubmed: 32084260
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
Am J Kidney Dis. 2022 May;79(5):760-764
pubmed: 34461166
Eur J Clin Pharmacol. 2021 Aug;77(8):1225-1234
pubmed: 33608749
Clin Nephrol. 2020 Jan;93(1):42-46
pubmed: 31670650
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Curr Oncol Rep. 2022 Jan;24(1):23-31
pubmed: 35059997
Am J Kidney Dis. 2021 Jun;77(6):990-992
pubmed: 33098925
Transplantation. 2014 Apr 15;97(7):755-61
pubmed: 24686425
Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):427-36
pubmed: 19358225
Blood Cancer J. 2020 Aug 5;10(8):79
pubmed: 32759935
J Am Soc Nephrol. 2018 Aug;29(8):2039-2052
pubmed: 29959196
Pharmaceuticals (Basel). 2020 Sep 21;13(9):
pubmed: 32967272
Lancet Oncol. 2018 Dec;19(12):1579-1589
pubmed: 30442497
Blood Rev. 2019 Mar;34:45-55
pubmed: 30528964